Current Rheumatology Reports

, Volume 4, Issue 4, pp 299–305 | Cite as

Evidence of involvement of central neural mechanisms in generating fibromyalgia pain

  • Roland Staud

Abstract

Fibromyalgia syndrome (FMS) is characterized by widespread pain, fatigue, sleep abnormalities, and distress. Because FMS lacks consistent evidence of tissue abnormalities, recent investigations have focused on central nervous system mechanisms of pain. Abnormal temporal summation of second pain (wind-up) and central sensitization have been described recently in patients with FMS. Windup and central sensitization, which rely on central pain mechanisms, occur after prolonged C-nociceptor input and depend on activation of nociceptor-specific neurons and wide dynamic range neurons in the dorsal horn of the spinal cord. Other abnormal central pain mechanisms recently detected in patients with FMS include diffuse noxious inhibitory controls. These pain inhibitory mechanisms rely on spinal cord and supraspinal systems involving pain facilitatory and pain inhibitory pathways. Brain-imaging techniques that can detect neuronal activation after nociceptive stimuli have provided additional evidence for abnormal central pain mechanisms in FMS. Brain images have corroborated the augmented reported pain experience of patients with fibromyalgia during experimental pain stimuli. In addition, thalamic activity, which contributes significantly to pain processing, was decreased in fibromyalgia. However, central pain mechanisms of fibromyalgia may not depend exclusively on neuronal activation. Neuroglial activation has been found to play an important role in the induction and maintenance of chronic pain. These findings may have important implications for future research and the treatment of fibromyalgia pain.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Treede RD, Meyer RA, Raja SN, Campbell JN: Peripheral and central mechanisms of cutaneous hyperalgesia. Prog Neurobiol 1992, 38:397–421.PubMedCrossRefGoogle Scholar
  2. 2.
    Simms RW, Roy SH, Hrovat M, et al.: Lack of association between fibromyalgia syndrome and abnormalities in muscle energy metabolism. Arthritis Rheum 1994, 37:794–800.PubMedCrossRefGoogle Scholar
  3. 3.
    De StefanoR, Selvi E, Villanova M, et al.: Image analysis quantification of substance P immunoreactivity in the trapezius muscle of patients with fibromyalgia and myofascial pain syndrome. J Rheumatol 2000, 27:2906–2910.PubMedGoogle Scholar
  4. 4.
    Li J, Simone DA, Larson AA: Windup leads to characteristics of central sensitization. Pain 1999, 79:75–82.PubMedCrossRefGoogle Scholar
  5. 5.
    Wall PD, Woolf CJ: Muscle but not cutaneous C-afferent input produces prolonged increases in the excitability of the flexion reflex in the rat. J Physiol (Lond) 1984, 356:443–458.Google Scholar
  6. 6.
    Mendell LM, Wall PD: Responses of single dorsal cord cells to peripheral cutaneous unmyelinated fibres. Nature 1965, 206:97–99.PubMedCrossRefGoogle Scholar
  7. 7.
    Davies SN, Lodge D: Evidence for involvement of N-methylaspartate receptors in ‘wind-up’ of class 2 neurones in the dorsal horn of the rat. Brain Res 1987, 424:402–406.PubMedCrossRefGoogle Scholar
  8. 8.
    Dickenson AH, Sullivan AF: Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropharmacology 1987, 26:1235–1238.PubMedCrossRefGoogle Scholar
  9. 9.
    Dickenson AH: A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol Sci 1990, 11:307–309.PubMedCrossRefGoogle Scholar
  10. 10.
    Price DD: Characteristics of second pain and flexion reflexes indicative of prolonged central summation. Exp Neurol 1972, 37:371–387.PubMedCrossRefGoogle Scholar
  11. 11.
    Price DD, Hu JW, Dubner R, Gracely RH: Peripheral suppression of first pain and central summation of second pain evoked by noxious heat pulses. Pain 1977, 3:57–68.PubMedCrossRefGoogle Scholar
  12. 12.
    Woolf CJ, Costigan M: Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci U S A 1999, 96:7723–7730.PubMedCrossRefGoogle Scholar
  13. 13.
    Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD: Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001, 91:165–175. Although wind-up was evoked in controls and patients with fibromyalgia syndrome (FMS), clear differences were observed. The perceived magnitude of the sensory response to the first stimulus within a series was greater for patients with FMS compared with controls, as was the amount of temporal summation within a series. Long-lasting aftersensations indicated central sensitization.PubMedCrossRefGoogle Scholar
  14. 14.
    Graven-Nielsen T, Aspegren KS, Henriksson KG, et al.: Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000, 85:483–491.PubMedCrossRefGoogle Scholar
  15. 15.
    Pall ML: Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Med Hypotheses 2000, 54:115–125.PubMedCrossRefGoogle Scholar
  16. 16.
    Pall ML: Common etiology of posttraumatic stress disorder, fibromyalgia, chronic fatigue syndrome and multiple chemical sensitivity via elevated nitric oxide/peroxynitrite. Med Hypotheses 2001, 57:139–145.PubMedCrossRefGoogle Scholar
  17. 17.
    Gebhard F, Nussler AK, Rosch M, et al.: Early posttraumatic increase in production of nitric oxide in humans. Shock 1998, 10:237–242.PubMedCrossRefGoogle Scholar
  18. 18.
    Larson AA, Giovengo SL, Russell IJ, Michalek JE: Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000, 87:201–211.PubMedCrossRefGoogle Scholar
  19. 19.
    Graven-Nielsen T, Aspegren-Kendall S, Bengtsson M, et al.: Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000, 85:483–491.PubMedCrossRefGoogle Scholar
  20. 20.
    Liu H, Brown JL, Jasmin L, et al.: Synaptic relationship between substance P and the substance P receptor: light and electron microscopic characterization of the mismatch between neuropeptides and their receptors. Proc Natl Acad Sci U S A 1994, 91:1009–1013.PubMedCrossRefGoogle Scholar
  21. 21.
    Liu H, Wang H, Sheng M, et al.: Evidence for presynaptic Nmethyl- D-aspartate autoreceptors in the spinal cord dorsal horn. Proc Natl Acad Sci U S A 1994, 91:8383–8387.PubMedCrossRefGoogle Scholar
  22. 22.
    Liu H, Mantyh PW, Basbaum AI: NMDA-receptor regulation of substance P release from primary afferent nociceptors. Nature 1997, 386:721–724.PubMedCrossRefGoogle Scholar
  23. 23.
    Curran T, Morgan JI: Fos: an immediate-early transcription factor in neurons. J Neurobiol 1995, 26:403–412.PubMedCrossRefGoogle Scholar
  24. 24.
    Coderre TJ, Katz J, Vaccarino AL, Melzack R: Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993, 52:259–285.PubMedCrossRefGoogle Scholar
  25. 25.
    Tsigos C, Diemel LT, White A, et al.: Cerebrospinal fluid levels of substance P and calcitonin-gene-related peptide: correlation with sural nerve levels and neuropathic signs in sensory diabetic polyneuropathy. Clin Sci Colch 1993, 84:305–311.PubMedGoogle Scholar
  26. 26.
    Vaeroy H, Helle R, Forre O, et al.: Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988, 32:21–26.PubMedCrossRefGoogle Scholar
  27. 27.
    Russell IJ, Orr MD, Littman B, et al.: Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994, 37:1593–1601.PubMedCrossRefGoogle Scholar
  28. 28.
    Watkins LR, Wiertelak EP, Furness LE, Maier SF: Illness-induced hyperalgesia is mediated by spinal neuropeptides and excitatory amino acids. Brain Res 1994, 664:17–24.PubMedCrossRefGoogle Scholar
  29. 29.
    Coderre TJ, Rollman GB: Stress analgesia: effects of PCPA, yohimbine, and naloxone. Pharmacol Biochem Behav 1984, 21:681–686.PubMedCrossRefGoogle Scholar
  30. 30.
    Martinez-Lavin M, Hermosillo AG, Rosas M, Soto ME: Circadian studies of autonomic nervous balance in patients with fibromyalgia: a heart rate variability analysis. Arthritis Rheum 1998, 41:1966–1971.PubMedCrossRefGoogle Scholar
  31. 31.
    Martinez-Lavin M, Hermosillo AG: Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia. Semin Arthritis Rheum 2000, 29:197–199.PubMedCrossRefGoogle Scholar
  32. 32.
    Anderberg UM, Liu Z, Berglund L, Nyberg F: Elevated plasma levels of neuropeptide Y in female fibromyalgia patients. Eur J Pain 1999, 3:19–30.PubMedCrossRefGoogle Scholar
  33. 33.
    Anderberg UM: Oxytocin and FMS. Z Rheumatol 2000, 59:373–379.PubMedCrossRefGoogle Scholar
  34. 34.
    Anderberg UM, Uvnas-Moberg K: Plasma oxytocin levels in female fibromyalgia syndrome patients. Z Rheumatol 2000, 59:373–379.PubMedCrossRefGoogle Scholar
  35. 35.
    Mannion RJ, Costigan M, Decosterd I, et al.: Neurotrophins: peripherally and centrally acting modulators of tactile stimulus-induced inflammatory pain hypersensitivity. Proc Natl Acad Sci U S A 1999, 96:9385–9390.PubMedCrossRefGoogle Scholar
  36. 36.
    Dyck PJ, Peroutka S, Rask C, et al.: Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans. Neurology 1997, 48:501–505.PubMedGoogle Scholar
  37. 37.
    Petty BG, Cornblath DR, Adornato BT, et al.: The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 1994, 36:244–246.PubMedCrossRefGoogle Scholar
  38. 38.
    Giovengo SL, Russell IJ, Larson AA: Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999, 26:1564–1569.PubMedGoogle Scholar
  39. 39.
    Woolf CJ, Safieh-Garabedian B, Ma QP, et al.: Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 1994, 62:327–331.PubMedCrossRefGoogle Scholar
  40. 40.
    Ruffolo R, Fuerstein GZ, Hunter AJ, et al.: Inflammatory Cells and Mediators in CNS Diseases. Amsterdam, The Netherlands: Harwood Academic Press; 1999.Google Scholar
  41. 41.
    Watkins LR, Maier SF: Cytokines and Pain: Progress in Inflammation Research. Boston, MA: Birkhauser; 1999.Google Scholar
  42. 42.
    Kreutzberg GW: Microglia: a sensor for pathological events in the CNS. Trends Neuroscience 1996, 19:312–318.CrossRefGoogle Scholar
  43. 43.
    Raivich G, Bluethmann H, Kreutzberg GW: Signaling molecules and neuroglial activation in the injured central nervous system. Keio J Med 1996, 45:239–247.PubMedGoogle Scholar
  44. 44.
    Wooten MW: Function for NF-êB in neuronal survival: regulation by atypical protein kinase C. J Neurosci Res 1999, 58:607–611.PubMedCrossRefGoogle Scholar
  45. 45.
    Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S: Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol 1997, 121:417–424.PubMedCrossRefGoogle Scholar
  46. 46.
    Watkins LR, Milligan ED, Maier SF: Spinal cord glia: new players in pain. Pain 2001, 93:201–205. Glial activation and its associated pro-inflammatory cytokine release are strongly implicated in the creation and maintenance of exaggerated pain states. Spinal cord glial activation has been linked to diverse pain states such as those arising from acute peripheral inflammation, chronic nerve trauma, and spinal infection.PubMedCrossRefGoogle Scholar
  47. 47.
    Watkins LR, Maier SF: The pain of being sick: implications of immune-to-brain communication for understanding pain. Annu Rev Psychol 2000, 51:29–57.PubMedCrossRefGoogle Scholar
  48. 48.
    Wood PL: Neuroinflammation: Mechanism and Management. Totowa: Humana; 2000.Google Scholar
  49. 49.
    Crinelli R, Antonelli A, Bianchi M, et al.: Selective inhibition of NF-êB activation and TNF-alpha production in macrophages by red blood cell-mediated delivery of dexamethasone. Blood Cells Mol Dis 2000, 26:211–222.PubMedCrossRefGoogle Scholar
  50. 50.
    Johansson A, Bennett GJ: Effect of local methylprednisolone on pain in a nerve injury model: a pilot study. Reg Anesth 1997, 22:59–65.PubMedCrossRefGoogle Scholar
  51. 51.
    Fields HL, Basbaum AI: Central nervous system mechanisms of pain modulation. In Textbook of Pain, edn 4. Edited by Wall PD, Melzack R. Edinburgh: Churchill Livingstone; 1999:309–329.Google Scholar
  52. 52.
    Willer JC, Roby A, Le Bars D: Psychophysical and electrophysiological approaches to the pain-relieving effects of heterotopic nociceptive stimuli. Brain 1984, 107:1095–1112.PubMedCrossRefGoogle Scholar
  53. 53.
    Villanueva L, Le Bars D: The activation of bulbo-spinal controls by peripheral nociceptive inputs: diffuse noxious inhibitory controls. Biol Res 1995, 28:113–125.PubMedGoogle Scholar
  54. 54.
    Bouhassira D, Villanueva L, Bing Z, Le Bars D: Involvement of the subnucleus reticularis dorsalis in diffuse noxious inhibitory controls in the rat. Brain Res 1992, 595:353–357.PubMedCrossRefGoogle Scholar
  55. 55.
    Staud R, Price DD, Vierck CJ, et al.: Diffuse noxious inhibitory controls (DNIC) do not inhibit wind-up of fibromyalgia patients. J Musculoskelet Pain 2001, 9:78.Google Scholar
  56. 56.
    Kosek E, Hansson P: Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain 1997, 70:41–51.PubMedCrossRefGoogle Scholar
  57. 57.
    Lautenbacher S, Rollman GB: Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain 1997, 13:189–196.PubMedCrossRefGoogle Scholar
  58. 58.
    Binder JR, Swanson SJ, Hammeke TA, et al.: Determination of language dominance using functional MRI: a comparison with the Wada test. Neurology 1996, 46:978–984.PubMedGoogle Scholar
  59. 59.
    Hui KKS, Liu J, Makris N, et al.: Acupuncture modulates the limbic system and subcortical gray structures of the human brain: evidence from fMRI studies in normal subjects. Hum Brain Mapp 2000, 9:13–25.PubMedCrossRefGoogle Scholar
  60. 60.
    Coghill RC, Talbot JD, Evans AC, et al.: Distributed processing of pain and vibration by the human brain. J Neurosci 1994, 14:4095–4108.PubMedGoogle Scholar
  61. 61.
    Coghill RC, Sang CN, Berman KF, et al.: Global cerebral blood flow decreases during pain. J Cereb Blood Flow Metab 1998, 18:141–147.PubMedCrossRefGoogle Scholar
  62. 62.
    Coghill RC, Gilron I, Iadarola MJ: Hemispheric lateralization of somatosensory processing. J Neurophysiol 2001, 85:2602–2612.PubMedGoogle Scholar
  63. 63.
    Xu X, Fukuyama H, Yazawa S, et al.: Functional localization of pain perception in the human brain studied by PET. Neuroreport 1997, 8:555–559.PubMedCrossRefGoogle Scholar
  64. 64.
    Jones AK, Brown WD, Friston KJ, et al.: Cortical and subcortical localization of response to pain in man using positron emission tomography. Proc R Soc Lond B Biol Sci 1991, 244:39–44.CrossRefGoogle Scholar
  65. 65.
    Sakiyama Y, Sato A, Senda M, et al.: Positron emission tomography reveals changes in global and regional cerebral blood flow during noxious stimulation of normal and inflamed elbow joints in anesthetized cats. Exp Brain Res 1998, 118:439–446.PubMedCrossRefGoogle Scholar
  66. 66.
    Di Piero V, Jones AK, Iannotti F, et al.: Chronic pain: a PET study of the central effects of percutaneous high cervical cordotomy. Pain 1991, 46:9–12.PubMedCrossRefGoogle Scholar
  67. 67.
    Hofbauer RK, Rainville P, Duncan GH, Bushnell MC: Cortical representation of the sensory dimension of pain. J Neurophysiol 2001, 86:402–411.PubMedGoogle Scholar
  68. 68.
    Mountz JM, Bradley LA, Modell JG, et al.: Fibromyalgia in women: abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 1995, 38:926–938.PubMedCrossRefGoogle Scholar
  69. 69.
    Kwiatek R, Barnden L, Tedman R, et al.: Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum 2000, 43:2823–2833.PubMedCrossRefGoogle Scholar
  70. 70.
    Petzke F, Clauw DJ, Wolf JM, Gracely RH: Pressure pain in fibromyalgia and healthy control: functional MRI of subjective pain experience versus objective stimulus intensity. Arthritis Rheum 2000, 43:S400.CrossRefGoogle Scholar
  71. 71.
    Petzke F, Clauw DJ, Khine A, Gracely RH: Increased pain sensitivity in fibromyalgia: effect of two types of stimuli and ascending versus random modes of presentation. Arthritis Rheum 2000, 43:S173.Google Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Roland Staud
    • 1
  1. 1.Division of Rheumatology and Clinical ImmunologyUniversity of FloridaGainesvilleUSA

Personalised recommendations